1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortal- ity worldwide: Sources, methods and major patterns in GLOBOCAN 2012. International Journal of Can- cer. 2015; 136: E359–E386. https://doi.org/10.1002/ijc.29210 PMID: 25220842
2. Dearden S, Stevens J, Wu Y-LL, Blowers D. Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap). Annals of oncology: official journal of the European Society for Medical Oncology / ESMO. 2013; 24: 2371–6. https://doi.org/10.1093/annonc/ mdt205 PMID: 23723294
3. Guo G, Gong K, Wohlfeld B, Hatanpaa KJ, Zhao D, Habib AA. Ligand-Independent EGFR Signaling. Cancer research. 2015; 75: 3436–41. https://doi.org/10.1158/0008-5472.CAN-15-0989 PMID: 26282175
4. Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C, et al. Screening for epidermal growth fac- tor receptor mutations in lung cancer. The New England journal of medicine. 2009; 361: 958–67. https:// doi.org/10.1056/NEJMoa0904554 PMID: 19692684
5. Sequist LV, Bell DW, Lynch TJ, Haber DA. Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. Journal of Clinical Oncology. 2007; 25: 587–595. Available: jco.ascopubs.org PMID: 17290067
6. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating muta- tions in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. The New England journal of medicine. 2004; 350: 2129–39. https://doi.org/10.1056/ NEJMoa040938 PMID: 15118073
7. Paez J, Ja¨ nne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: corre- lation with clinical response to gefitinib therapy. Science (New York, NY). 2004; 304: 1497–500. https:// doi.org/10.1126/science.1099314 PMID: 15118125
8. Lindeman NI, Cagle PT, Aisner DL, Arcila ME, Beasley MB, Bernicker EH, et al. Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. Journal of thoracic oncol- ogy: official publication of the International Association for the Study of Lung Cancer. 2018; 13: 323–358. https://doi.org/10.1016/j.jtho.2017.12.001 PMID: 29396253
9. Yatabe Y, Kerr KM, Utomo A, Rajadurai P, Tran VK, Du X, et al. EGFR mutation testing practices within the Asia Pacific region: results of a multicenter diagnostic survey. Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer. 2015; 10: 438–45. https://doi. org/10.1097/JTO.0000000000000422 PMID: 25376513
10. Naoki K, Soejima K, Okamoto H, Hamamoto J, Hida N, Nakachi I, et al. The PCR-invader method (structure-specific 5’ nuclease-based method), a sensitive method for detecting EGFR gene mutations in lung cancer specimens; comparison with direct sequencing. International journal of clinical oncology. 2011; 16: 335–44. https://doi.org/10.1007/s10147-011-0187-5 PMID: 21311943
11. Nagai Y, Miyazawa H, Huqun, Tanaka T, Udagawa K, Kato M, et al. Genetic heterogeneity of the epi- dermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp. Cancer research. 2005; 65: 7276–82. https://doi.org/10.1158/0008-5472.CAN-05-0331 PMID: 16105816
12. Goto K, Satouchi M, Ishii G, Nishio K, Hagiwara K, Mitsudomi T, et al. An evaluation study of EGFR mutation tests utilized for non-small-cell lung cancer in the diagnostic setting. Annals of oncology: offi- cial journal of the European Society for Medical Oncology / ESMO. 2012; 23: 2914–9. https://doi.org/10. 1093/annonc/mds121 PMID: 22776705
13. Ikami M, Kawakami A, Kakuta M, Okamoto Y, Kaji N, Tokeshi M, et al. Immuno-pillar chip: a new plat- form for rapid and easy-to-use immunoassay. Lab on a chip. 2010; 10: 3335–40. https://doi.org/10. 1039/c0lc00241k PMID: 20959907
14. Yamamichi A, Kasama T, Ohka F, Suzuki H, Kato A, Motomura K, et al. An immuno-wall microdevice exhibits rapid and sensitive detection of IDH1-R132H mutation specific to grade II and III gliomas. Sci- ence and technology of advanced materials. 2016; 17: 618–625. https://doi.org/10.1080/14686996. 2016.1227222 PMID: 27877908
15. Hase T, Sato M, Yoshida K, Girard L, Takeyama Y, Horio M, et al. Pivotal role of epithelial cell adhesion molecule in the survival of lung cancer cells. Cancer science. 2011; 102: 1493–500. https://doi.org/10. 1111/j.1349-7006.2011.01973.x PMID: 21535318
16. Kitamura A, Hosoda W, Sasaki E, Mitsudomi T, Yatabe Y. Immunohistochemical Detection of EGFR Mutation Using Mutation-Specific Antibodies in Lung Cancer. Clinical Cancer Research. 2010; 16: 3349–55. https://doi.org/10.1158/1078-0432.CCR-10-0129 PMID: 20570926
17. Kato Y, Peled N, Wynes MW, Yoshida K, Pardo M, Mascaux C, et al. Novel epidermal growth factor receptor mutation-specific antibodies for non-small cell lung cancer: immunohistochemistry as a possi- ble screening method for epidermal growth factor receptor mutations. Journal of thoracic oncology: offi- cial publication of the International Association for the Study of Lung Cancer. 2010; 5: 1551–8. https:// doi.org/10.1097/JTO.0b013e3181e9da60 PMID: 20697298
18. Simonetti S, Molina M, Queralt C, de Aguirre I, Mayo C, Bertran-Alamillo J, et al. Detection of EGFR mutations with mutation-specific antibodies in stage IV non-small-cell lung cancer. Journal of Transla- tional Medicine. 2010; 8: 1–8. https://doi.org/10.1186/1479-5876-8-1 PMID: 20064266
19. Brevet M, Arcila M, Ladanyi M. Assessment of EGFR mutation status in lung adenocarcinoma by immu- nohistochemistry using antibodies specific to the two major forms of mutant EGFR. The Journal of molecular diagnostics: JMD. 2010; 12: 169–76. https://doi.org/10.2353/jmoldx.2010.090140 PMID: 20093391
20. Wu S-GG, Chang Y-LL, Lin J-WW, Wu C-TT, Chen H-YY, Tsai M-FF, et al. Including total EGFR stain- ing in scoring improves EGFR mutations detection by mutation-specific antibodies and EGFR TKIs response prediction. PloS one. 2011; 6: e23303. https://doi.org/10.1371/journal.pone.0023303 PMID: 21858063
21. Kozu Y, Tsuta K, Kohno T, Sekine I, Yoshida A, Watanabe S, et al. The usefulness of mutation-specific antibodies in detecting epidermal growth factor receptor mutations and in predicting response to tyro- sine kinase inhibitor therapy in lung adenocarcinoma. Lung cancer (Amsterdam, Netherlands). 2011; 73: 45–50. https://doi.org/10.1016/j.lungcan.2010.11.003 PMID: 21129809
22. Hofman P, Ilie M, Hofman V, Roux S, Valent A, Bernheim A, et al. Immunohistochemistry to identify EGFR mutations or ALK rearrangements in patients with lung adenocarcinoma. Annals of Oncology. 2012; 23: 1738–1743. https://doi.org/10.1093/annonc/mdr535 PMID: 22100693
23. Kawahara A, Yamamoto C, Nakashima K, Azuma K, Hattori S, Kashihara M, et al. Molecular diagnosis of activating EGFR mutations in non-small cell lung cancer using mutation-specific antibodies for immu- nohistochemical analysis. Clinical cancer research: an official journal of the American Association for Cancer Research. 2010; 16: 3163–70. https://doi.org/10.1158/1078-0432.CCR-09-3239 PMID: 20423982
24. Xiong Y, Bai Y, Leong N, Laughlin TS, Rothberg PG, Xu H, et al. Immunohistochemical detection of mutations in the epidermal growth factor receptor gene in lung adenocarcinomas using mutation-spe- cific antibodies. Diagnostic pathology. 2013; 8: 27. https://doi.org/10.1186/1746-1596-8-27 PMID: 23419122
25. Bellevicine C, Bianco A, Malapelle U, Luca CD, Vigliar E, Cacciola NA, et al. Performance of EGFR mutant-specific antibodies in different cytological preparations: a validation study. Cytopathology: offi- cial journal of the British Society for Clinical Cytology. 2015; 26: 99–105. https://doi.org/10.1111/cyt. 12155 PMID: 24831172
26. Seo AN, Park T-II, Jin Y, Sun P-LL, Kim H, Chang H, et al. Novel EGFR mutation-specific antibodies for lung adenocarcinoma: highly specific but not sensitive detection of an E746_A750 deletion in exon 19 and an L858R mutation in exon 21 by immunohistochemistry. Lung cancer (Amsterdam, Netherlands). 2014; 83: 316–23. https://doi.org/10.1016/j.lungcan.2013.12.008 PMID: 24412618
27. Mok TS, Wu Y-LL, Thongprasert S, Yang C-HH, Chu D-TT, Saijo N, et al. Gefitinib or carboplatin-pacli- taxel in pulmonary adenocarcinoma. The New England journal of medicine. 2009; 361: 947–57. https:// doi.org/10.1056/NEJMoa0810699 PMID: 19692680
28. Yu J, Kane S, Wu J, Benedettini E, Li D, Reeves C, et al. Mutation-specific antibodies for the detection of EGFR mutations in non-small-cell lung cancer. Clinical cancer research: an official journal of the American Association for Cancer Research. 2009; 15: 3023–8. https://doi.org/10.1158/1078-0432.CCR-08-2739 PMID: 19366827
29. Eberhard DA, Giaccone G, Johnson BE, Group N-S-CLCW. Biomarkers of Response to Epidermal Growth Factor Receptor Inhibitors in Non–Small-Cell Lung Cancer Working Group: Standardization for Use in the Clinical Trial Setting. J Clin Oncol. 2008; 26: 983–994. https://doi.org/10.1200/JCO.2007.12. 9858 PMID: 18281673
30. Pirker R, Herth FJF, Kerr KM, Filipits M, Taron M, Gandara D, et al. Consensus for EGFR Mutation Testing in Non-small Cell Lung Cancer: Results from a European Workshop. J Thorac Oncol. 2010; 5: 1706–1713. https://doi.org/10.1097/JTO.0b013e3181f1c8de PMID: 20871269
31. Oliner K, Juan T, Suggs S, Wolf M, Sarosi I, Freeman DJ, et al. A comparability study of 5 commercial KRAS tests. Diagn Pathol. 2010; 5: 23. https://doi.org/10.1186/1746-1596-5-23 PMID: 20398393